Cambridge Investment Research Advisors
EDIT icon

Cambridge Investment Research Advisors’s Editas Medicine EDIT Stock Holding History

Cambridge Investment Research Advisors’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$524K Sell
161,878
-16,605
-9% -$48.5K ﹤0.01% 2911
2026
Q1 		$441K Sell
178,483
-3,104
-2% -$6.57K ﹤0.01% 2915
2025
Q4 		$372K Buy
181,587
+3,198
+2% +$9.23K ﹤0.01% 2991
2025
Q3 		$619K Buy
178,389
+1,785
+1% +$4.98K ﹤0.01% 2471
2025
Q2 		$389K Buy
176,604
+90,888
+106% +$149K ﹤0.01% 2772
2025
Q1 		$99K Sell
85,716
-631
-0.7% -$928 ﹤0.01% 3351
2024
Q4 		$110K Buy
86,347
+11,926
+16% +$30.4K ﹤0.01% 3317
2024
Q3 		$254K Buy
74,421
+474
+0.6% +$2.06K ﹤0.01% 2954
2024
Q2 		$345K Sell
73,947
-3,335
-4% -$18.8K ﹤0.01% 2590
2024
Q1 		$573K Sell
77,282
-2,367
-3% -$19.7K ﹤0.01% 2166
2023
Q4 		$807K Buy
79,649
+4,204
+6% +$36.9K ﹤0.01% 1801
2023
Q3 		$588K Buy
75,445
+2,453
+3% +$21K ﹤0.01% 1949
2023
Q2 		$601K Buy
72,992
+8,243
+13% +$71.8K ﹤0.01% 1990
2023
Q1 		$469K Buy
64,749
+722
+1% +$6.42K ﹤0.01% 2133
2022
Q4 		$568K Sell
64,027
-2,444
-4% -$26.8K ﹤0.01% 1915
2022
Q3 		$814K Buy
66,471
+1,159
+2% +$18.1K ﹤0.01% 1614
2022
Q2 		$773K Buy
65,312
+752
+1% +$10.1K ﹤0.01% 1655
2022
Q1 		$1.23M Sell
64,560
-1,316
-2% -$24.5K 0.01% 1432
2021
Q4 		$1.75M Sell
65,876
-111,405
-63% -$3.83M 0.01% 1223
2021
Q3 		$7.28M Buy
177,281
+82,042
+86% +$4.5M 0.04% 460
2021
Q2 		$5.39M Buy
95,239
+401
+0.4% +$14.8K 0.03% 582
2021
Q1 		$3.98M Sell
94,838
-6,586
-6% -$375K 0.02% 666
2020
Q4 		$7.11M Buy
101,424
+91,908
+966% +$3.78M 0.04% 398
2020
Q3 		$267K Sell
9,516
-5,091
-35% -$166K ﹤0.01% 2027
2020
Q2 		$432K Buy
14,607
+1,887
+15% +$49.3K ﹤0.01% 1642
2020
Q1 		$252K Buy
12,720
+5,012
+65% +$126K ﹤0.01% 1779
2019
Q4 		$228K Buy
+7,708
New +$193K ﹤0.01% 2113
2018
Q3 		– Sell
-5,594
Closed -$200K – 2255
2018
Q2 		$200K Sell
5,594
-646
-10% -$22.9K ﹤0.01% 2016
2018
Q1 		$207K Buy
+6,240
New +$222K ﹤0.01% 1941

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Cambridge Investment Research Advisors's EDIT Position: Q2 2026 in Review

Cambridge Investment Research Advisors reduced its Editas Medicine (EDIT) stake by 9.3% in Q2 2026, selling an estimated $48.5K and leaving 161,878 shares worth $524K. The position accounts for ﹤0.01% of the portfolio, ranked #2911.

Cambridge Investment Research Advisors first reported a position in EDIT in Q1 2018 and has held it in 29 quarters since. The position peaked at $7.28M in Q3 2021. 214 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Cambridge Investment Research Advisors held 161,878 shares of Editas Medicine worth $524K as of Q2 2026.
  • Cambridge Investment Research Advisors sold 16,605 Editas Medicine shares in Q2 2026, an estimated $48.5K.
  • Editas Medicine made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #2911 holding.
  • Cambridge Investment Research Advisors first reported a position in Editas Medicine in Q1 2018 and has held it in 29 quarters since.
  • Cambridge Investment Research Advisors's Editas Medicine position peaked at $7.28M in Q3 2021.
  • 214 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.